Tumor molecular profiling is central for prognosis and treatment planning [6], mirrored in the WHO 2016 classifications, where isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations and alpha thalassemia/mental retardation syndrome X-linked (ATRX), among others, were incorporated as diagnostic criteria for tumors of glial origin [6,7,8]. Here, ATRX is linked to alpha thalassemia spectrum.